Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

被引：0
|
作者：
Janne B Kjersem
Tone Ikdahl
Tormod Guren
Eva Skovlund
Halfdan Sorbye
Julian Hamfjord
Per Pfeiffer
Bengt Glimelius
Christian Kersten
Hiroko Solvang
Kjell M Tveit
Elin H Kure
机构：
[1] Institute for Cancer Research,Department of Genetics
[2] Oslo University Hospital,Department of Oncology
[3] Oslo University Hospital,School of Pharmacy
[4] University of Oslo and the Norwegian Institute of Public Health,Department of Oncology
[5] Haukeland University Hospital,Department of Oncology
[6] Odense University Hospital,Department of Radiology, Oncology and Radiation Science
[7] Uppsala University,Department of Oncology and Pathology
[8] Karolinska Institutet,Center for Cancer Treatment
[9] Southern Hospital Trust,undefined
来源：
BMC Cancer | / 12卷
关键词：
Colorectal cancer; LCS6; MiRNA polymorphism; Cetuximab; Oxaliplatin; 5-fluorouracil;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Erratum: Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?
    L Paré
    E Marcuello
    A Altés
    E del Rio
    L Sedano
    A Barnadas
    M Baiget
    The Pharmacogenomics Journal, 2009, 9 : 218 - 218
  • [22] GENETIC MODULATION OF THE LET-7 MICRO-RNA BINDING TO KRAS 3′-UNTRANSLATED REGION (3′-UTR) IMPACTS ON SURVIVAL OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH UNRESPONSIVE DISEASE TO SALVAGE CETUXIMAB-IRINOTECAN
    Graziano, Francesco
    Canestrari, Emanuele
    Loupakis, Fotios
    Ruzzo, Annamaria
    Santini, Daniele
    Galluccio, Nadia
    Vincenzi, Bruno
    Salvatore, Lisa
    Cremolini, Chiara
    Spoto, Chiara
    Schirripa, Marta
    Catalano, Vincenzo
    D'Emidio, Silvia
    Giordani, Paolo
    Alessandroni, Paolo
    Falcone, Alfredo
    Tonini, Giuseppe
    Magnani, Mauro
    ANNALS OF ONCOLOGY, 2009, 20
  • [23] A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer
    Ryan, DP
    Clark, JW
    Kulke, MH
    Fuchs, CS
    Earle, CC
    Enzinger, PC
    Stuart, K
    Catarius, KJ
    Winkelmann, J
    Mayer, RJ
    CANCER INVESTIGATION, 2003, 21 (04) : 505 - 511
  • [24] Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
    Mekenkamp, Leonie J. M.
    Tol, Jolien
    Dijkstra, Jeroen R.
    de Krijger, Inge
    Vink-Borger, M. Elisa
    van Vliet, Shannon
    Teerenstra, Steven
    Kamping, Eveline
    Verwiel, Eugene
    Koopman, Miriam
    Meijer, Gerrit A.
    van Krieken, J. Han J. M.
    Kuiper, Roland
    Punt, Cornelis J. A.
    Nagtegaal, Iris D.
    BMC CANCER, 2012, 12
  • [25] The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients
    Sebio, Ana
    Pare, Laia
    Paez, David
    Salazar, Juliana
    Gonzalez, Alan
    Sala, Nuria
    del Rio, Elisabeth
    Martin-Richard, Marta
    Tobena, Maria
    Barnadas, Agusti
    Baiget, Montserrat
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (03): : 142 - 147
  • [26] Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with cetuximab
    Bando, H.
    Yoshino, T.
    Shinozaki, E.
    Yuki, S.
    Nishina, T.
    Kadowaki, S.
    Yamazaki, K.
    Tsuchihara, K.
    Fujii, S.
    Yamanaka, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [27] Association of FcgRIIa and FcgRIIIa polymorphisms and kras mutations with clinical outcome in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan
    Bibeau, F.
    Crapez, E.
    Di Fiore, F.
    Thezenas, S.
    Sabourin, J.
    Lamy, A.
    Frebourg, T.
    Michel, P.
    Ychou, M.
    Boissiere, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 27 - 27
  • [28] Becam: A salvage protocol with bevacizumab, capecitabin, and mitomycin C for patients with metastatic colorectal or gastric cancer refractory to 5-fluorouracil, oxaliplatin, irinotecan, and cetuximab
    Peinert, SP
    Grothe, WG
    Kuehne, IK
    Kegel, TK
    Arnold, DA
    Schmoll, HJS
    ANNALS OF ONCOLOGY, 2006, 17
  • [29] Salvage therapy with bevacizumab, capecitabin, and mitomycin C (BECAM) for patients with metastatic colorectal or gastric cancer refractory to 5-fluorouracil, oxaliplatin, irinotecan, and cetuximab
    Peinert, S.
    Arnold, D.
    Grothe, W.
    Lesske, J.
    Siewczynski, R.
    Schaedlich, B.
    Kegel, T.
    Behrmann, C.
    Schmoll, H.-J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 226
  • [30] Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
    Leonie JM Mekenkamp
    Jolien Tol
    Jeroen R Dijkstra
    Inge de Krijger
    M Elisa Vink-Börger
    Shannon van Vliet
    Steven Teerenstra
    Eveline Kamping
    Eugène Verwiel
    Miriam Koopman
    Gerrit A Meijer
    J Han JM van Krieken
    Roland Kuiper
    Cornelis JA Punt
    Iris D Nagtegaal
    BMC Cancer, 12
12345